Drugs / ESBA105
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00671619 | Apr → Jul 2008 | — | ESBATech AG | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00820014 | Jan 2009 → Sep 2010 | cataract | ESBATech AG | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01338610 | Jun 2011 → Feb 2012 | dry eye syndrome | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00823173 | Jan 2009 → Dec 2010 | anterior uveitis | ESBATech AG | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ESBA105 | “ESBA105 is a topically administered tumour necrosis factor alpha (TNF-alpha) inhibitor that has significant therapeutic potential in various inflammatory intraocular diseases.” NCT00820014 ↗ |
| Action | Inhibit | “tumour necrosis factor alpha (TNF-alpha) inhibitor” NCT00820014 ↗ |
| Modality | Monoclonal antibody | “anti TNF single chain antibody fragment” NCT00671619 ↗ |
| Route | Topical | “ESBA105 administered topically to the eye” NCT00671619 ↗ |
| Target | TNF | “anti TNF single chain antibody fragment” NCT00671619 ↗ |